Dataset opportunity
Starseq — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Starseq, usable for Diagnostic AI and Computer Vision.
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Genomics market to reach USD 1.7 billion in 2026, with a 40.3% CAGR (2026-2033).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
Participation in BMBF-funded genomics research projects (GlioTraceGenOmics, OmicsGlioma)
source ↗ - ✨Signal
Developing a proprietary collection of novel genes for human illness and animal/plant models
source ↗ - 🤝Data partnership
Scientific partner for microbAIome project investigating host-microbiome interactions
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Starseq holds a valuable collection of proprietary gene collections and associated R&D datasets, combining genomic data from sequencing with linked medical imaging and patient records. This multi-modal dataset constitutes a significant dormant asset, perfectly suited for training and validating high-performance Diagnostic AI models aimed at biomarker discovery, disease prediction, and personalizing treatment pathways.
Despite access complexities, such as GDPR compliance for sensitive genomic information and the need to segregate client-owned data, the asset's value is underscored by a booming market. The global AI in Genomics market is projected to grow from USD 1.7 billion in 2026 to USD 18.8 billion by 2033, driven by an explosive CAGR of 40.3%. [1] This makes Starseq's unique, proprietary data a rare and highly sought-after resource for buyers developing next-generation diagnostic tools. ⚠ Diligence (valuable data, access to negotiate): Genomic data is highly GDPR-sensitive and requires strict ethical/legal compliance; Standard sequencing results are typically client-owned, requiring clear separation from proprietary R&D data; Proprietary gene collections and R&D datasets are the primary dormant assets · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Starseq generates and curates high-value genomic data, including from Whole Exome Sequencing and high-throughput profiling. The company is actively building a proprietary collection of novel genes explicitly linked to human illness, a core asset for training next-generation diagnostic AI. For medical-AI and diagnostic firms, this is a direct path to the foundational data needed to compete in the AI in Genomics market, a sector projected to grow at over 40% annually.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
AI buyer demand is exceptionally high, driven by the AI in Genomics market's rapid expansion at a 40.3% CAGR, creating intense competition for proprietary genomic and clinical datasets. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 evidence types, 4 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 data-appetite signals (3 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 4 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ review — This is a fee-for-service laboratory whose core business is generating DNA sequence data for its clients; it does not own the data and therefore has no dormant data to sell. Issues: The company's business is providing DNA sequencing as a service; the resulting data is the deliverable for the client, not a proprietary by-product owned by Sta; The company explicitly states that the client's 'samples, results, data and IP are safe', implying the client retains ownership. [5]; The initial
- Deep Qualification90
✓ pass — Starseq is primarily a genomic services provider (CRO), meaning data from its core business is customer-owned. However, its internal R&D projects, such as 'GlioTraceGenOmics', plausibly generate proprietary, multi-modal datasets (genomics + clinical data), which represent a dormant asset. The 'Medic
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<p>When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform the “greatest credible competitive threat in years.”</p>”
- “<p>Queue is developing automated pharmacies to expand access to prescriptions in hospitals, retail sites, and underserved communities.</p> <p>The post <a href="https://www.therobotreport.com/queue-raises-funding-fully-autonomous-pharmacy/">Queue raises funding to build fully autonomous pharmacy</a> appeared first on <a href="https://www.therobotreport.com">The Robot Report</a>.</p>”
- “<p>The acquisition strengthens Agilent’s presence in areas including cancer and infectious disease diagnostic and research markets.</p>”
Downloads / exports
This evidence of commercial promotions confirms Starseq is an active, scaled provider of genomic sequencing services, indicating a consistent operational flow of NGS and microbiome data.
Medical records / imaging
This sample confirms the company's capability in advanced analysis like Whole Exome Sequencing and gene expression profiling, the exact processes that generate rich, foundational data for diagnostic AI.
Data catalog / marketplace
This is direct evidence of a strategic effort to build a proprietary collection of novel genes linked to human illness, representing a curated, high-value asset for AI development.
Industrial data
This sample demonstrates the company's broad expertise in molecular genetics, including microbiome analysis, which underpins the quality and diversity of their data generation capabilities.
Marketplace
Dataset details
Geographic coverage
Global
Time range
Not specified, likely historical with periodic updates
Update frequency
Periodic
Delivery
Likely secure file transfer or API access
License
One-time license for training and validation of diagnostic AI models, subject to GDPR and data segregation requirements.
Personal data
Contains PII
Indicative estimate, derived from public signals — not a quote, not contractual, and not agreed with the company. Is this your company? Correct it.
This multi-modal dataset, combining proprietary genomic data with linked medical imaging and patient records, is highly valuable for training diagnostic AI. The strong market growth in AI in Genomics supports a premium valuation.
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Starseq Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Genomics market to reach USD 1.7 billion in 2026, with a 40.3% CAGR (2026-2033) (source: Grand View Research). Investment score 45.0/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
13Therapeutics — Medical Imaging Dataset Opportunity
View opportunity →healthcareComprehensivesleepcare — Medical Imaging Dataset Opportunity
View opportunity →healthcareKardium — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Is Your Data Worth Money?3 min read
- What is a Dataset Worth?3 min read
- How a Data Transaction Works3 min read